Lost Patent Protection? Move To China, Says Specialty Biotech SciClone
This article was originally published in PharmAsia News
Executive Summary
The value of brand in China has helped SciClone consistently grow sales of its branded flagship product Zadaxin even with no IP protection and significant generic competition. Indicated for hepatitis B and hepatitis C, Zadaxin has generated $80 million in sales in China and is the backbone of the small biotech company
You may also be interested in...
Death By EDL Inclusion? Pfizer And SciClone Drop Cancer Drugs In China
Manufacturers are reevaluating products and reducing sales forces in response to pricing pressure that includes an expanded Essential Drug List in China.
Death By EDL Inclusion? Pfizer And SciClone Drop Cancer Drugs In China
Manufacturers are reevaluating products and reducing sales forces in response to pricing pressure that includes an expanded Essential Drug List in China.
SciClone Takes Deeper Plunge In China Following Solid Q1 Results
SciClone sees more opportunities ahead as it plans deeper expansion into China, following Q1 results that posted a 38% increase in sales for its lead product.